-
Innovative Pharma (00399) terminates clinics acquisition
Innovative Pharmaceutical Biotech (00399) said it agreed to terminate the memorandum of understanding for a proposed acquisition of the 
controlling interest in HK.DNA Diagnostics Centre Limited, Hong Kong Modern Medical
Service Limited and Modern Medical Specialties Limited.
The target group consists of three limited liability companies all of which were 
incorporated in Hong Kong. The principal business operation of the target group is to
provide one-stop accredited medical consultation and health examination services in Hong 
Kong. The target group currently operates three clinics which are situated in Tsim Sha 
Tsui, Mong Kok and Causeway Bay, respectively.
The company considers the termination would not have any material adverse impact on its
existing business operation. It will continue to explore other potential investment
opportunities to strengthen the profitability.

Comments

Post a Comment

Popular posts from this blog

-
Image
CITIC Annual Net Profit Up 1.8% to $43.902B; Final Div $0.25 CITIC (00267.HK)    -0.160 (-1.447%)    Short selling $8.89M; Ratio 25.055%   announced that for the year ended December 2017, net profit rose 1.8% yearly to $43.902 billion, with an EPS of $1.51. A final dividend of $0.25 was declared. Profit contribution from financial sector of the company amounted to $39.5 billion, up 3% yearly. CITIC Construction continued to make inroads securing projects, both domestically and internationally, particularly along the Belt and Road corridor.
Read more
-
CLSA lowers Beijing Ent Water (00371) to HK$6   CLSA cut its target price for Beijing Enterprises Water (BEW)(00371) by 8% to HK$6, and reiterated its "buy" rating.   The research house said BEW's share price has dropped 14% in the last two trading days. First, the 2017 earnings results are below expectations. Second, management is guiding for 20-25% net profit growth for 2018, versus 30% in the past few years. Management now has a cautious approach to water PPP (public-private partnership) projects, which is not  necessarily bad.   CLSA cut its 2018-19 earnings forecasts by...
Read more
-
Image
HAECO (00044.HK) 2017 Loss $540M, 2nd Interim Div. $0.5   AECO (00044.HK)    -0.250 (-0.530%)      Short selling $18.92K; Ratio 2.633%     announced annual results for the period ended 31 December 2017. The loss amounted to $541 million, against the profit of $975 million in the year-ago period. Loss per share equaled $3.25. A second interim dividend of $0.5 was declared.
Read more